# EDGAR Filing Document

**Accession Number:** 0002061651
**File Stem:** 0001104659-25-116066
**Filing Date:** 2025-11
**Character Count:** 13007
**Document Hash:** 36c9abd21a8ae6a7ccb57185fde119ba
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-116066.hdr.sgml**: 20251125

**ACCESSION NUMBER**: 0001104659-25-116066

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251121

**FILED AS OF DATE**: 20251125

**DATE AS OF CHANGE**: 20251125

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** CK Life Sciences Intl (Holdings) Inc
- **CENTRAL INDEX KEY:** 0001297567

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39811
- **FILM NUMBER:** 251522815

**BUSINESS ADDRESS:**
- **STREET 1:** 7TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** CENTRAL
- **STATE:** K3
- **ZIP:** -
- **BUSINESS PHONE:** 852 2128 8888

**MAIL ADDRESS:**
- **STREET 1:** 7TH FLOOR, CHEUNG KONG CENTER
- **STREET 2:** 2 QUEEN'S ROAD CENTRAL
- **CITY:** CENTRAL
- **STATE:** K3
- **ZIP:** -
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Conjoint Inc.
- **CENTRAL INDEX KEY:** 0002061651

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** K3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39811
- **FILM NUMBER:** 251522816

**BUSINESS ADDRESS:**
- **STREET 1:** 2 DAI FU STREET
- **STREET 2:** TAI PO INDUSTRIAL ESTATE
- **CITY:** NEW TERRITORIES
- **STATE:** K3
- **ZIP:** 00000
- **BUSINESS PHONE:** (852) 2126 1661

**MAIL ADDRESS:**
- **STREET 1:** 2 DAI FU STREET
- **STREET 2:** TAI PO INDUSTRIAL ESTATE
- **CITY:** NEW TERRITORIES
- **STATE:** K3
- **ZIP:** 00000
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Sealbond Ltd
- **CENTRAL INDEX KEY:** 0002040446

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** D8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39811
- **FILM NUMBER:** 251522817

**BUSINESS ADDRESS:**
- **STREET 1:** 2 DAI FU ST., TAI PO INDUSTRIAL ESTATE
- **STREET 2:** NEW TERRITORIES
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 00000
- **BUSINESS PHONE:** (852) 2126 1661

**MAIL ADDRESS:**
- **STREET 1:** 2 DAI FU ST., TAI PO INDUSTRIAL ESTATE
- **STREET 2:** NEW TERRITORIES
- **CITY:** HONG KONG
- **STATE:** K3
- **ZIP:** 00000
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dogwood Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001818844
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 854314201
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 44 MILTON AVENUE
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30009
- **BUSINESS PHONE:** 8666208655

**MAIL ADDRESS:**
- **STREET 1:** 44 MILTON AVENUE
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30009

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Virios Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20201217

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Virios Therapeutics, LLC
- **DATE OF NAME CHANGE:** 20200721

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Sealbond Ltd<br><sub>(Last) (First) (Middle)</sub><br>2 DAI FU STREET,<br>TAI PO INDUSTRIAL ESTATE<br><sub>(Street)</sub><br>NEW TERRITORIES, K3 <br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-21 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_See Remarks_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Dogwood Therapeutics, Inc. [ DWTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Conjoint Inc.<br><sub>(Last) (First) (Middle)</sub><br>2 DAI FU STREET,<br>TAI PO INDUSTRIAL ESTATE<br><sub>(Street)</sub><br>NEW TERRITORIES, K3 <br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-21 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_See Remarks_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Dogwood Therapeutics, Inc. [ DWTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>CK Life Sciences Intl (Holdings) Inc<br><sub>(Last) (First) (Middle)</sub><br>2 DAI FU STREET,<br>TAI PO INDUSTRIAL ESTATE<br><sub>(Street)</sub><br>NEW TERRITORIES, K3 <br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-21 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[ ] Officer (give title below) [X] Other (specify below)<br>_See Remarks_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Dogwood Therapeutics, Inc. [ DWTX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-21 |  | C<sup>(1)</sup> |  | 21610950 | A | <sup>(1)</sup> | 21822333 | D<sup>(2)</sup> |  |
| Common Stock | 2025-11-21 |  | C<sup>(1)</sup> |  | 2842638 | A | <sup>(1)</sup> | 2842638 | I<sup>(3)</sup> | By Conjoint Inc. |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Series A Preferred Stock | <sup>(1)</sup> | 2025-11-21 |  | C<sup>(1)</sup> |  |  | 2161.095<sup>(4)</sup> | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 21610950 | $0 | 0 | D<sup>(2)</sup> |  |
| Series A-1 Preferred Stock | <sup>(1)</sup> | 2025-11-21 |  | C<sup>(1)</sup> |  |  | 284.2638 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 2842638 | $0 | 0 | I<sup>(3)</sup> | By Conjoint Inc. |

---

### Footnotes:

(1) On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

(2) Sealbond Limited, a British Virgin Islands limited company ("Sealbond"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company ("Kamfull"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company ("Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability ("CKLS"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

(3) Shares are held directly by Conjoint Inc., a Delaware corporation ("Conjoint"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company ("Honglad"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company ("ENSO Resources"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

(4) Includes 52.7096 shares of Series A Preferred Stock previously issued to Sealbond as a payment-in-kind dividend that was exempt from Section 16 pursuant to Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

**Remarks:**
Mr. Yu Ying Choi Alan Abel ("Mr. Yu"), the Deputy Chairman of CKLS, and Dr. Toh Kean Meng Melvin ("Dr. Toh"), the Vice President and Chief Scientific Officer and Executive Director of CKLS, have been appointed to the board of directors of the Issuer, and each of Mr. Yu and Dr. Toh have been deputized to represent the Reporting Person on the board of directors. By virtue of Mr. Yu and Dr. Toh's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer. Mr. Yu and Dr. Toh have filed separate Section 16 reports disclosing securities of the Issuer that each may respectively be deemed to beneficially own for Section 16 purposes.

**Signature:** /s/ Wong Wun Lam, Director of Sealbond Limited  
**Date:** 2025-11-25

**Signature:** /s/ Yu Ying Choi Alan Abel, Director of Conjoint Inc.  
**Date:** 2025-11-25

**Signature:** /s/ Yu Ying Choi Alan Abel, Director of CK Life Sciences Int'l., (Holdings) Inc.  
**Date:** 2025-11-25

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**